Kiritkumar Parmar, MD
Internal Medicine · Vineland, NJNPI 1396813614
Payments from drug & device makers
Across 150 payments — averaging $14.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$530
- Boehringer Ingelheim$219
- Lilly USA, LLC$156
- Abbott$125
- Pfizer$124
- Amgen$124
- plus $912 from 22 others
What the payments were for
- Food & beverage$2,191100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 39 | $530 |
| Boehringer Ingelheim | 16 | $219 |
| Lilly USA, LLC | 10 | $156 |
| Abbott | 8 | $125 |
| Pfizer | 9 | $124 |
| Amgen | 8 | $124 |
| Johnson & Johnson | 7 | $102 |
| AstraZeneca | 7 | $100 |
| Merck | 7 | $99 |
| AbbVie | 4 | $61 |
| Sanofi-aventis U.S. LLC | 4 | $55 |
| Exact Sciences | 2 | $54 |
| Boston Scientific | 2 | $53 |
| Sunovion Pharmaceuticals Inc. | 4 | $46 |
| Philips North America LLC | 3 | $45 |
| Amarin Pharma, Inc. | 3 | $39 |
| Bayer | 2 | $36 |
| Kowa Pharmaceuticals America, Inc. | 2 | $33 |
| GSK | 2 | $29 |
| Novartis | 2 | $26 |
| Astellas Pharma US Inc | 2 | $26 |
| Soleno Therapeutics, Inc. | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Sumitomo Pharma America, Inc. | 1 | $13 |
| Sun Pharmaceutical Industries Inc. | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
| Daiichi Sankyo Inc. | 1 | $11 |
How this compares
$2,191 in reported general payments places this provider in the 75th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 72 | $105,644 |
| RybelsusSemaglutide | 48 | $83,524 |
| JardianceEmpagliflozin | 58 | $81,386 |
| EliquisApixaban | 89 | $57,752 |
| FarxigaDapagliflozin Propanediol | 67 | $50,691 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 58 | $47,202 |
| InvokanaCanagliflozin | 17 | $27,537 |
| ProliaDenosumab | 15 | $26,469 |
| MounjaroTirzepatide | 24 | $26,141 |
| XareltoRivaroxaban | 20 | $23,115 |
| OzempicSemaglutide | 13 | $18,859 |
| LinzessLinaclotide | 24 | $13,254 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $12,124 |
| Bydureon BciseExenatide Microspheres | 12 | $11,191 |
| MyrbetriqMirabegron | 19 | $10,321 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia | $99 | $105,64472 claims |
| Novo NordiskRybelsus, Ozempic | $530 | $102,38361 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $219 | $86,52769 claims |
| PfizerEliquis | $124 | $57,75289 claims |
| AstraZenecaFarxiga | $100 | $50,69167 claims |
| Johnson & JohnsonInvokana, Xarelto | $102 | $50,65137 claims |
| GSKTrelegy Ellipta | $29 | $47,20258 claims |
| AmgenProlia | $124 | $26,46915 claims |
| Lilly USA, LLCMounjaro | $156 | $26,14124 claims |
| AbbVieLinzess, Synthroid | $61 | $15,83451 claims |
| Astellas Pharma US IncMyrbetriq | $26 | $10,32119 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $55 | $8,27911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Vineland
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
- Sumitha ReddyHamilton$2M
- Helio PedroNewark$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.